Economic Evaluation of Positron Emission Tomography (PET) in Non Small Cell Lung Cancer (NSCLC), CHERE Working Paper 2007/6

HTBS Bradbury
et al, (2002),
Scotland

a) All to surgery

b) Palliatation

c) Mediastinoscopy

d) Mediastinoscopy with
PET after a negative
mediastinoscopy.

e) PET

f) PET with
mediastinoscopy

Potential
Operable
NSCLC

Cost Utility

Quality adjusted
life year (QALYs)

Decision
Analysis

a) 2.88 QALYS
b) 1.46 QALYS
c) 2.89 QALYS
d) 2.76 QALYS
e) 2.77 QALYS
f) 2.76 QALYS
g) 2.91 QALYS

a) 4,467
b) 6,105

c) 4,642
d) 5,137

e) 4,899
f) 5,124

g) 4, 854

c) vs a)
£18,589/QALY
gained
g) vs c)
£10,475/QALY
gained

b, d, e and f were
all dominated by
g.

Dietlein et al

a) Conventional staging -

Potentially

Cost

Unnecessary

Decision

a) 3.30 LYs

a) 16, 890

b) vs a) €143/LY

2000. Germany

CT and Mediastinoscopy

b) Whole body FDG-PET
in patients with negative
CT

c) Whole body FDG-PET
in all patients - if positive
PET then Mediastinoscopy

d) Whole body FDG-PET
in all patients - excluded
form surgery if positive
PET and Positive CT

Whole body FDG-PET in
all patients - excluded
from surgery if positive
PET

operable
NSCLC

effectiveness

Thoractomies

Analysis

b) 3.32 LYs

c) 3.33 LYs

d) 3.39 LYs

e) 3.36 LYs

b) 16,892

c) 17,712

d) 16, 279

e) 15, 839

gained

c) vs b) €36,6670/
LY gained.